ID

38766

Descrizione

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01691755

collegamento

https://clinicaltrials.gov/show/NCT01691755

Keywords

versioni (2)
  1. 02/11/19 02/11/19 -
  2. 02/11/19 02/11/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

2 novembre 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Diabetes Mellitus, Type 2 NCT01691755

Inglese

Eligibility Diabetes Mellitus, Type 2 NCT01691755

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, >/=18 years of age
Descrizione

Adult | Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
diagnosis of diabetes mellitus, type 2 within 12 months prior to screening
Descrizione

Non-Insulin-Dependent Diabetes Mellitus Disease length

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
patients who have not received a anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past
Descrizione

Hypoglycemic Agents Absent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020616
UMLS CUI [1,2]
C0332197
hba1c >/=7% and </=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
Descrizione

Hemoglobin A1c measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0474680
fasting plasma glucose </=240 mg/dl at pre-randomization visit
Descrizione

Plasma fasting glucose measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0583513
agreement to maintain diet and exercise habits during the study
Descrizione

Diet therapy Maintenance | Exercise Habits Maintenance

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012159
UMLS CUI [1,2]
C0024501
UMLS CUI [2,1]
C0015259
UMLS CUI [2,2]
C0018464
UMLS CUI [2,3]
C0024501
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months
Descrizione

Diabetes Mellitus, Insulin-Dependent | Secondary diabetes mellitus | Diabetes Mellitus Due to Injury of pancreas | Complications of Diabetes Mellitus Metabolic

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011854
UMLS CUI [2]
C0271640
UMLS CUI [3,1]
C0011849
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C0273163
UMLS CUI [4,1]
C0342257
UMLS CUI [4,2]
C0311400
any previous treatment with thiazolidinedione or a dual ppar agonist
Descrizione

Thiazolidinediones | Peroxisome Proliferator-Activated Receptor Agonist Dual

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2,1]
C0166418
UMLS CUI [2,2]
C2987634
UMLS CUI [2,3]
C0205173
any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)
Descrizione

Weight reduction regimen | Lipoprotein modification Therapy | Exception Statins Dose Stable

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0311130
UMLS CUI [2,1]
C1158918
UMLS CUI [2,2]
C0087111
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0360714
UMLS CUI [3,3]
C0178602
UMLS CUI [3,4]
C0205360
symptomatic congestive heart failure classified as new york heart association class ii-iv at screening
Descrizione

Symptomatic congestive heart failure New York Heart Association Classification

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0742758
UMLS CUI [1,2]
C1275491
Ritorna all'inizio della pagina

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT01691755

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patients, >/=18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
diagnosis of diabetes mellitus, type 2 within 12 months prior to screening
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Hypoglycemic Agents Absent
Item
patients who have not received a anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past
boolean
C0020616 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Hemoglobin A1c measurement
Item
hba1c >/=7% and </=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
boolean
C0474680 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
fasting plasma glucose </=240 mg/dl at pre-randomization visit
boolean
C0583513 (UMLS CUI [1])
Diet therapy Maintenance | Exercise Habits Maintenance
Item
agreement to maintain diet and exercise habits during the study
boolean
C0012159 (UMLS CUI [1,1])
C0024501 (UMLS CUI [1,2])
C0015259 (UMLS CUI [2,1])
C0018464 (UMLS CUI [2,2])
C0024501 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent | Secondary diabetes mellitus | Diabetes Mellitus Due to Injury of pancreas | Complications of Diabetes Mellitus Metabolic
Item
patients with type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months
boolean
C0011854 (UMLS CUI [1])
C0271640 (UMLS CUI [2])
C0011849 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0273163 (UMLS CUI [3,3])
C0342257 (UMLS CUI [4,1])
C0311400 (UMLS CUI [4,2])
Thiazolidinediones | Peroxisome Proliferator-Activated Receptor Agonist Dual
Item
any previous treatment with thiazolidinedione or a dual ppar agonist
boolean
C1257987 (UMLS CUI [1])
C0166418 (UMLS CUI [2,1])
C2987634 (UMLS CUI [2,2])
C0205173 (UMLS CUI [2,3])
Weight reduction regimen | Lipoprotein modification Therapy | Exception Statins Dose Stable
Item
any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)
boolean
C0311130 (UMLS CUI [1])
C1158918 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0360714 (UMLS CUI [3,2])
C0178602 (UMLS CUI [3,3])
C0205360 (UMLS CUI [3,4])
Symptomatic congestive heart failure New York Heart Association Classification
Item
symptomatic congestive heart failure classified as new york heart association class ii-iv at screening
boolean
C0742758 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial